Back

The real-world cost and health resource utilization associated to the CNIC-polypill containing Atorvastatin 20mg in secondary prevention patients: a subanalysis of the NEPTUNO study

15 April 2023 (11:35 - 11:46)
Organised by:
Congress Presentation Part of: Late-Breaking Science session Public Health and Health Economics, Other EAPC Premium Access ESC Preventive Cardiology 2023

About the speaker

Photo
Doctor Alberto Cordero

Hospital San Juan de Alicante, Alicante (Spain)

4 More presentations in this session

Presentation thumbnail
Real-world early effectiveness and safety of inclisiran in China Pilot Zone: An interim analysis of 3-month data from a prospective non-interventional cohort study
Ms Y. Qiao (CN)
Slides Video
Presentation thumbnail
Prolonged moderate-intensity exercise does not increase muscle injury markers in symptomatic or asymptomatic statin users
Mrs N. Allard (Nijmegen, NL)
Slides Video
Presentation thumbnail
Flemish study on environment, genes and health outcomes
Assistant Professor N. Cauwenberghs (Leuven, BE)
Slides Video
Presentation thumbnail
Prevalence of new-onset diabetes mellitus, associated factors and outcomes of hyperglycemia on mortality among hospitalized COVID-19 patients
Doctor F. Kalokola (Mwanza, TZ)

Access the full session

Session thumbnail
Late-Breaking Science session

The Event

Event poster

ESC Preventive Cardiology 2023

15 April 2023 11:35 CET
You may be interested in
thumbnail
Congress Presentation
Polypill: a drug for everyone?
thumbnail
Congress Presentation
The cardiovascular polypill: simplicity to tackle a complex problem
thumbnail
Congress Presentation
The cardiovascular polypill strategy (acetyl salicylic acid, atorvastatin, ramipril) as baseline treatment after a cardiovascular event supported by compelling evidence: a global expert consensus

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources